Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: A GITMO prospective randomized study

Haematologica

Volumn 89, Issue 9, 2004, Pages 1054-1061

  Locasciulli, Anna ^a   Bruno, Barbara ^b   Rambaldi, Alessandro ^c   Saracco, Paola ^d   Dufour, Carlo ^e   Finelli, Carlo ^f   Sica, Simona ^g   Varotto, Stefania ^h   Arcese, William ⁱ   Locatelli, Franco ^j   Soligo, Davide ^k   Bacigalupo, Andrea ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Ospedale Civile   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF PAVIA   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Acquired aplastic anemia; G CSF dose; Immunosuppression

Indexed keywords

CIPROFLOXACIN; CYCLOSPORIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; AGE; AGED; APLASTIC ANEMIA; ARTICLE; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SURVIVAL RATE; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ANEMIA, APLASTIC; ANIMALS; ANTILYMPHOCYTE SERUM; BLOOD CELL COUNT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HORSES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIFE TABLES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 4644343664     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Young NS. Acquired aplastic anemia. Ann Intern Med 2002;136:534-46.
2. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000; 37:3-14.
3. Bacigalupo A, Brand R, Oneto R, Bruno B, Sociè G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy. The European Group for Blood and Marrow Transplantation Experience. Semin Hematol 2000;37:69-80.
4. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1983;308:113-8.
5. Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rapeerport JM, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood 1979;53:504-14.
6. Doney K, Martin P, Storb R, Whitehead J, Smith A, Hansen JA, et al. A randomized trial of antihuman thymocyte globulin versus murine monoclonal antihuman T-cell antibodies as immunosuppressive therapy for aplastic anemia. Exp Hematol 1985;13:520-4.
7. Frickofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, for the German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: a 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
8. Bacigalupo A, Chaple M, Hows J, Van Lint MT, McCann S, Milligan D, et al. Treatment of aplastic anemia (AA) with antilymphocyte globulin (ALG) and methyl-prednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol 1993;83:145-51.
9. Schrezenmeier H, Bacigalupo A, Aglietta A, Camitta B, Frickhofen N, Fuhrer M, et al. Consensus document for treating aplastic anemia, of a group of international experts In: Schrezenmeioer H, Bacigalupo A, eds. Aplastic anaemia: pathophysiology and treatment. Cambridge University Press. 2000. p. 308-15.
10. Marsh JCW, Socié G, Schrezenmeier H, Tichelli A, Glukman E, Ljungman P, et al. for the European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Haematopoietic growth factors in aplastic anaemia: a cautionary note. Lancet 1994;344:172-3.
11. Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, et al. for the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midollo Osseo (GITMO). Antilymphocyte globulin, cyclosporine, prednisone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95:1931-4.
12. Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, et al. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol 2002;119:1075-82.
13. Locasciulli A, Arcese W, Locatelli F, Di Bona E, Bacigalupo A, for the Italian Aplastic Anaemia Study group. Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet 2001;357:43-4.
14. Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, et al. Japan Childhood Aplastic Anemia Study Group. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children. Blood 2002;100:786-90.
15. Bacigalupo A, Piaggio G, Podestà M, van Lint MT, Valbonesi M, Lercari G, et al. Collection of peripheral blood hemopoietic progenitors (PBHP) from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony-stimulating factor. Blood 1993; 82:1410-4.
16. Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, et al. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol 1994; 87:609-13.
17. Tichelli A, Socié G, Henry-Amar M, Marsh J, Passweg J, Schrezenmeier H, et al for the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. Ann Intern Med 1999;130:193-201.
18. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA 2003;289: 1130-5.
19. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236-42.
20. Sociè G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, et al. Malignant tumors occurring after treatment of aplastic anemia. N Engl J Med 1993;329:1152-7.
21. Kojima S, Hibi S, Koska Y, Yamamoto M, Tsuchida M, Mugishima H, et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. The Japan Childhood Aplastic Anemia Study Group. Blood 2000;96:2049-54.
22. Ohara A, Kojima S, Hamajima N, Tsuchida M, Imashuku S, Ohta S, et al. Myelodysplastic syndrome and acute myelogenous leukemia as late clonal complications in children with acquired aplastic anemia. Blood 1997;90:1009-13.